APA (7th ed.) Citation

JL, C., M, Y., L, P., AL, P., JN, S., YFI, S., . . . TR, C. (2023). A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nature cancer, 4(9), 1326. https://doi.org/10.1038/s43018-023-00614-y

Chicago Style (17th ed.) Citation

JL, Chitty, et al. "A First-in-class Pan-lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic Cancer." Nature Cancer 4, no. 9 (2023): 1326. https://doi.org/10.1038/s43018-023-00614-y.

MLA (9th ed.) Citation

JL, Chitty, et al. "A First-in-class Pan-lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic Cancer." Nature Cancer, vol. 4, no. 9, 2023, p. 1326, https://doi.org/10.1038/s43018-023-00614-y.